TCM
TEVA icon

Trent Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Trent Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$4.72M Buy
+142,197
New +$4.4M 7.02% 6
2016
Q4 		$3.73M Buy
+102,870
New +$4.11M 4.17% 11

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Trent Capital Management's TEVA Position: Q2 2017 in Review

Trent Capital Management opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2017: 142,197 shares worth $4.72M. The stake represents 7.02% of the portfolio and ranks #6 among its holdings. This is a return to the name: Trent Capital Management previously reported a position in TEVA as recently as Q4 2016.

Trent Capital Management first reported a position in TEVA in Q4 2016 and has held it in 2 quarters since. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

  • Trent Capital Management held 142,197 shares of Teva Pharmaceuticals worth $4.72M as of Q2 2017.
  • Teva Pharmaceuticals was a new Trent Capital Management position in Q2 2017.
  • Teva Pharmaceuticals made up 7.02% of Trent Capital Management's portfolio in Q2 2017, its #6 holding.
  • Trent Capital Management first reported a position in Teva Pharmaceuticals in Q4 2016 and has held it in 2 quarters since.
  • 648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Trent Capital Management's 13F filing for Q2 2017, filed 1 Aug 2017.